8-K: ImmuCell Reports Mixed Q4, Strong FY25 Sales Amid Strategic Shift

ImmuCell announced preliminary Q4 2025 sales declined 1.6% to $7.6 million, while full-year 2025 sales rose 4.3% to $27.6 million, alongside a strategic pivot from Re-Tain to First Defense.

Summary

• Preliminary unaudited total sales for Q4 2025 were $7.6 million, a 1.6% decrease compared to Q4 2024.
• Preliminary unaudited total sales for the full year 2025 were $27.6 million, a 4.3% increase compared to full year 2024.
• The company is strategically shifting focus from its Re-Tain product to expanding its First Defense product line.
• This shift follows an FDA Incomplete Letter for Re-Tain due to contract manufacturer deficiencies, leading to a decision to pause further investment.
• ImmuCell expects to record approximately $3.6 million in non-cash impairment write-downs during Q4 2025, including $2.9 million related to Re-Tain assets.
• The majority of the $15.5 million net book value of Re-Tain assets (as of September 30, 2025) will be repurposed for First Defense expansion.
• Manufacturing output for the lyophilization process increased by over 15% year-over-year in 2025, with further improvements planned for 2026.
• The company plans a 50% expansion of its sales force, adding two domestic territories and an international business development executive.

Sentiment

Score: 6

Explanation: While Q4 sales saw a slight decline, full-year sales were positive, and management expressed exceeding expectations for the quarter. The strategic pivot from the troubled Re-Tain product to focus on the successful First Defense line, coupled with plans for manufacturing expansion and sales force growth, shows a proactive approach to challenges. However, the significant write-downs and the need for capital for repurposing assets introduce some financial headwinds and uncertainty. The international sales decline is also a concern.

Positives

• Full year 2025 total sales increased by 4.3% to $27.6 million compared to 2024.
• Domestic sales for Q4 2025 increased by 8.7% to $7.0 million compared to Q4 2024.
• Domestic sales for full year 2025 increased by 6.5% to $24.4 million compared to full year 2024.
• Tri-Shield sales for Q4 2025 increased by 41.3% to $6.0 million compared to Q4 2024.
• Tri-Shield sales for full year 2025 increased by 26.5% to $19.9 million compared to full year 2024.
• Q4 sales exceeded management's expectations, indicating progress in rebuilding market position.
• Manufacturing output of the lyophilization process increased by over 15% year-over-year in 2025.
• Plans to repurpose the majority of $15.5 million in Re-Tain assets for First Defense expansion, enhancing future liquid processing capacity.
• Initiated a 50% expansion of the sales force to support commercial growth.

Negatives

• Total sales for Q4 2025 declined by 1.6% to $7.6 million compared to Q4 2024.
• International sales for Q4 2025 declined by 52.6% to $0.6 million compared to Q4 2024.
• International sales for full year 2025 declined by 9.6% to $3.3 million compared to full year 2024.
• Dual-Force and other sales for Q4 2025 declined by 53.0% to $1.7 million compared to Q4 2024.
• Dual-Force and other sales for full year 2025 declined by 28.2% to $7.7 million compared to full year 2024.
• Decision to pause further investment in the Re-Tain product due to an FDA Incomplete Letter and contract manufacturer deficiencies.
• Expectation to record approximately $3.6 million in non-cash impairment write-downs in Q4 2025, including $2.9 million for Re-Tain assets, $0.1 million for other property, plant, and equipment, and $0.6 million for inventory.
• The repurposing of Re-Tain assets for First Defense requires additional capital for building modifications, which is currently being assessed.

Risks

• Difficulties or delays in the development, testing, regulatory approval, production, and marketing of products.
• Competition within anticipated product markets.
• Customer acceptance of new and existing products.
• Product performance.
• Alignment between manufacturing resources and product demand.
• Uncertainty associated with the timing and volume of customer orders.
• Adverse impacts of possible future supply chain disruptions or shortfalls on operations and customer/supplier relationships.
• Commercial and operational risks related to current and planned expansion of First Defense production capacity.
• Future implications of prior regulatory inspection deficiencies relating to facilities of the company's contract manufacturer.
• Inability to attract partners for Re-Tain or maximize its value.
• Actual timing, fair values, and impairment charges may differ materially from current estimates.

Future Outlook

The company expects to continue providing prompt, preliminary reports on product sales. It plans to expand its liquid processing capacity for First Defense by repurposing Re-Tain assets, though this requires capital for building modifications, which is currently being assessed. Further manufacturing improvements are planned for 2026 with minimal capital investment to meet First Defense growth targets. The company is expanding its sales force by 50% and intends to complete investigational studies for Re-Tain to attract partners and maximize its value. The focus in coming quarters will be on commercial expansion and creating scalable manufacturing capacity.

Management Comments

• "Sales for the quarter exceeded our expectations and show that we continue to make progress rebuilding our market position after a period of supply challenges." Olivier te Boekhorst, President and CEO.
• "This was one of our highest sales quarters ever, without tailwinds from catching up on backorders. Our international business showed a decline, largely due to order timing." Olivier te Boekhorst, President and CEO.
• "We are highly encouraged by the strong growth of our Tri-Shield product line, which reflects the migration from Dual-Force products and the acquisition of new dairy and beef customers seeking protection for their calves." Olivier te Boekhorst, President and CEO.
• "The deployment of these assets for First Defense will expand our liquid processing capacity to meet our needs well into the future, but requires capital for repurposing the building which we are currently assessing." Timothy C. Fiori, Chief Financial Officer.
• "In the meantime, we have implemented manufacturing improvements that increased output of our lyophilization process by more than 15% year-over-year in 2025 and we plan similar improvements in 2026 with minimal capital investment. This gives us confidence we can meet growth targets for First Defense." Timothy C. Fiori, Chief Financial Officer.
• "We use a rigorous and disciplined approach to assessing the best-and-highest value use of our resources and have determined that we expect to achieve a higher return from selling this particular colostrum in the market without further processing." Timothy C. Fiori, Chief Financial Officer.
• "We are confident in our ability to source and process high quality colostrum going forward to meet demand." Timothy C. Fiori, Chief Financial Officer.
• "The strong sales results and excellent progress in expanding manufacturing output further support our decision to focus on First Defense." Olivier te Boekhorst, President and CEO.
• "Tri-Shield growth was outstanding, and we have now started a 50% expansion of the sales force by creating two new domestic territories and hiring an international business development executive." Olivier te Boekhorst, President and CEO.
• "We also plan to complete our ongoing investigational studies for Re-Tain to attract partners and maximize value. Combined with the successful manufacturing initiatives and the longer-term manufacturing capacity expansion leveraging the former Re-Tain building and equipment, we are very well positioned for continued growth." Olivier te Boekhorst, President and CEO.
• "In the coming quarters, our focus will be on commercial expansion and creating scalable manufacturing capacity to support that growth." Olivier te Boekhorst, President and CEO.

Industry Context

ImmuCell operates in the animal health sector, specifically focusing on products for cattle health and productivity. The strategic shift to prioritize First Defense, a product providing immediate immunity to newborn calves, aligns with a focus on established, revenue-generating products. The decline in Dual-Force sales and strong growth in Tri-Shield suggests a product migration within the First Defense line, indicating evolving market preferences or successful product differentiation. The challenges with the Re-Tain product, particularly regulatory hurdles related to contract manufacturing, highlight the complexities and risks inherent in the pharmaceutical and animal health regulatory landscape. The company's efforts to expand manufacturing capacity and sales force indicate a commitment to capturing market share in the calf immunity segment.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: Potential positive impact from increased focus on the successful First Defense product line and planned growth initiatives, but negative impact from significant non-cash write-downs and the discontinuation of Re-Tain development. Uncertainty regarding future capital needs for asset repurposing.
• Employees: Potential positive impact from sales force expansion and increased manufacturing capacity for First Defense, suggesting job stability or growth in those areas.
• Customers (Dairy and Beef Producers): Continued availability and potentially increased supply of First Defense products, including the growing Tri-Shield line, which offers protection for calves.
• Suppliers: Continued demand for colostrum and other raw materials for First Defense production.
• Creditors: The non-cash write-downs will impact the balance sheet, but the company does not expect material future cash expenditures from these charges. The need for capital for building repurposing could imply future financing activities.

Next Steps

• Host a conference call on January 9, 2026, to discuss preliminary sales results and the strategic shift.
• Release full, unaudited financial results for Q4 and full year 2025 after market close on February 25, 2026.
• Host a conference call on February 26, 2026, to discuss the full financial results.
• Complete ongoing investigational studies for Re-Tain to attract partners and maximize value.
• Assess capital requirements for repurposing the former Re-Tain building for First Defense liquid processing capacity.
• Implement similar manufacturing improvements in 2026 to increase lyophilization output with minimal capital investment.
• Continue commercial expansion and create scalable manufacturing capacity to support First Defense growth.
• Expand the sales force by 50% by creating two new domestic territories and hiring an international business development executive.

Key Dates

Recommendation

The filing presents a mixed bag of results and strategic shifts. While full-year sales growth and strong performance in the Tri-Shield product line are positive, the Q4 sales decline, significant write-downs related to the Re-Tain product, and the associated regulatory setback are concerning. The strategic pivot to First Defense is a necessary and potentially beneficial move, but it comes with immediate financial costs and future capital requirements for asset repurposing. The company's proactive steps in expanding manufacturing and sales are encouraging, but the overall picture suggests a period of transition and investment rather than immediate strong upside. Investors should hold to observe the execution of the First Defense expansion, the impact of the write-downs on future financials, and the success in attracting partners for Re-Tain.

Keywords

Animal Health, ImmuCell, ICCC, First Defense, Tri-Shield, Dual-Force, Re-Tain, SEC Filing, Sales Results, Q4 2025, Full Year 2025, FDA, Impairment, Write-down, Cattle Health, Calf Immunity, Biotechnology, Veterinary Medicine